



**HAL**  
open science

## Effect of lesogaberan, a novel GABAB-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects

Guy E Boeckxstaens, Hans Rydholm, Aaltje Lei, John Adler, Magnus Ruth

► **To cite this version:**

Guy E Boeckxstaens, Hans Rydholm, Aaltje Lei, John Adler, Magnus Ruth. Effect of lesogaberan, a novel GABAB-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. *Alimentary Pharmacology and Therapeutics*, 2010, 31 (11), pp.1208. 10.1111/j.1365-2036.2010.04283.x . hal-00552541

**HAL Id: hal-00552541**

**<https://hal.science/hal-00552541v1>**

Submitted on 6 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Effect of lesogaberan, a novel GABAB-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects**

Journal:	<i>Alimentary Pharmacology &amp; Therapeutics</i>
Manuscript ID:	APT-0981-2009.R1
Manuscript Type:	Original Scientific Paper
Date Submitted by the Author:	26-Feb-2010
Complete List of Authors:	Boeckxstaens, Guy; University Hospital Leuven, Catholic University of Leuven, Department of Gastroenterology; Academic Medical Center Rydholm, Hans; AstraZeneca R&D Mölndal Lei, Aaltje; Academic Medical Center Adler, John; AstraZeneca R&D Mölndal Ruth, Magnus; AstraZeneca R&D Mölndal
Keywords:	Oesophagus < Organ-based, GERD or GORD < Disease-based, X keyword = no topic , Y keyword = no topic

1  
2  
3  
4 **Effect of lesogaberan, a novel GABA<sub>B</sub>-receptor agonist, on**  
5  
6  
7 **transient lower esophageal sphincter relaxations in male subjects**  
8  
9

10  
11  
12  
13 **Authors:** GUY E. BOECKXSTAENS<sup>\*,†</sup>, HANS RYDHOLM<sup>‡</sup>, AALTJE LEI<sup>\*</sup>, JOHN  
14  
15  
16 ADLER<sup>‡</sup> & MAGNUS RUTH<sup>‡</sup>  
17

18  
19 <sup>\*</sup>Academic Medical Center, Amsterdam, the Netherlands; <sup>†</sup>University Hospital Leuven,  
20  
21 Catholic University of Leuven, Belgium; <sup>‡</sup>AstraZeneca R&D Mölndal, Sweden  
22  
23  
24  
25  
26  
27

28 **Short title:** Effect of lesogaberan on TLESRs  
29  
30

31 **Keywords:** lesogaberan, GABA<sub>B</sub> receptor agonists, gastroesophageal reflux disease, partial  
32  
33 response, transient lower esophageal sphincter relaxation  
34  
35

36  
37 **Word count:** 3959 (including tables)  
38  
39

40 **Correspondence to:**  
41

42  
43 Professor Dr Guy E. Boeckxstaens  
44

45  
46 Department of Gastroenterology  
47

48 University Hospital Leuven, Catholic University of Leuven  
49

50  
51 Herestraat 49  
52

53  
54 3000 Leuven  
55

56  
57 Belgium  
58

59  
60 Tel: +32 16 34 57 50

Fax: +32 16 33 02 38

E-mail: [guy.boeckxstaens@med.kuleuven.be](mailto:guy.boeckxstaens@med.kuleuven.be)

For Peer Review

## SUMMARY

**Background:** Transient lower esophageal sphincter relaxations (TLESRs) are a major mechanism behind gastroesophageal reflux disease (GERD).

**Aim:** To assess the effect of lesogaberan (AZD3355) – a novel peripherally active GABA<sub>B</sub> receptor agonist – on TLESRs.

**Methods:** Twenty-four healthy men were enrolled in this single-blind, placebo-controlled, randomized, single-centre, three-period crossover phase 1 study. Subjects were randomized to receive single oral doses of lesogaberan (0.8 mg/kg), baclofen (40 mg) and placebo, separated by washout periods of  $\leq 7$  days. Subjects finished a meal 1 hour after the dose. Esophageal manometry and pH-metry measurements were taken during the 3 hours after the meal.

**Results:** Twenty-one subjects completed the study. Compared with placebo, lesogaberan 0.8 mg/kg significantly reduced the number of TLESRs by 36% (geometric mean ratio [GMR]: 0.64; 95% confidence interval [CI]: 0.51–0.82) and significantly reduced the number of acid reflux episodes (mean reduction: 1.6; 95% CI: 0.34–2.9). Lesogaberan also significantly increased lower esophageal sphincter (LES) pressure by 39% compared with placebo (GMR: 1.39; 95% CI: 1.18–1.64). Comparable results were observed with baclofen. Similar numbers of adverse events were reported by subjects taking lesogaberan and placebo.

**Conclusions:** Compared with placebo, lesogaberan significantly reduced TLESRs and acid reflux episodes, and increased LES pressure.

## INTRODUCTION

Gastroesophageal reflux disease (GERD), characterized by troublesome heartburn and/or acid regurgitation, is a chronic condition that imposes a significant burden on patients.<sup>1-3</sup> Acid reflux is the major contributor to symptom generation in GERD<sup>4</sup> and acid suppression reduces associated symptoms and damage to the esophageal mucosa.<sup>5,6</sup> However, 20–30% of patients with GERD experience persistent reflux symptoms despite proton pump inhibitor (PPI) therapy.<sup>7-10</sup> Impedance monitoring in patients with GERD treated with a PPI revealed that symptoms can occur when the refluxate is only weakly acidic, and also when it is weakly alkaline.<sup>11,12</sup> There has therefore been growing interest in new therapeutic targets for GERD in addition to acid suppression, to help patients with a partial response to PPIs to achieve adequate symptom relief.

Targeting the lower esophageal sphincter (LES) to prevent reflux episodes is an attractive approach because it offers a new mode of action that could complement the acid-suppressive effects of a PPI by reducing all types of reflux. Much interest has been focused on transient lower esophageal sphincter relaxation (TLESR), the predominant mechanism underlying reflux in healthy individuals and in patients with GERD.<sup>13,14</sup> TLESRs are modulated by the neurotransmitter  $\gamma$ -aminobutyric acid (GABA) acting on GABA type B (GABA<sub>B</sub>) receptors, which are located in the peripheral nervous system as well as in the brainstem.<sup>15,16</sup> Studies in healthy subjects and individuals with GERD have shown that the GABA<sub>B</sub>-receptor agonist, baclofen, which is indicated for spasticity, reduces the number of TLESRs and reflux episodes, including weakly acidic and weakly alkaline reflux.<sup>17-19</sup> Furthermore, when added to existing PPI therapy, baclofen reduces reflux symptoms and the number of reflux episodes in patients with persistent GERD symptoms despite PPI treatment.<sup>20</sup> However, the adverse

1  
2  
3 effects of baclofen in the central nervous system (CNS) limit its clinical usefulness in the  
4  
5 treatment of GERD, and therefore baclofen is not indicated for this disease.<sup>18</sup>  
6  
7  
8  
9

10 Lesogaberan (AZD3355) is a competitive, selective GABA<sub>B</sub>-receptor agonist that dose-  
11  
12 dependently inhibits TLESRs and reduces the number of reflux episodes and esophageal acid  
13  
14 exposure in dogs.<sup>21,22</sup> Lesogaberan has been shown to reduce the activation of ferret gastric  
15  
16 vagal mechanoreceptors,<sup>23</sup> indicating that it has a peripheral site of action. It has a high  
17  
18 affinity for the GABA carrier, which results in low extracellular lesogaberan levels in the  
19  
20 CNS, so there is relatively little potential for this agent to interact with central GABA<sub>B</sub>  
21  
22 receptors.<sup>23</sup> These data support the concept that lesogaberan inhibits TLESRs through a  
23  
24 peripheral site of action and has a lower propensity for CNS adverse effects than baclofen.  
25  
26  
27  
28  
29  
30

31 The current study is the first to assess the pharmacodynamic effects of the novel GABA<sub>B</sub>-  
32  
33 receptor agonist lesogaberan in humans. The primary objective was to assess the effect of  
34  
35 oral lesogaberan on the number of TLESRs in healthy males. The study also aimed to  
36  
37 measure the effect of lesogaberan on the number of acid reflux episodes and on LES pressure,  
38  
39 and to assess tolerability. Although not indicated for GERD, baclofen was used as a positive  
40  
41 control for measuring the effect of lesogaberan on TLESRs.  
42  
43  
44  
45  
46  
47

## 48 **METHODS**

### 49 **Study participants**

50  
51 Male subjects aged 18–50 years, weighing 65–100 kg with a body mass index of 19–  
52  
53 30 kg/m<sup>2</sup>, and having no clinically abnormal physical findings or laboratory values at the  
54  
55 time of the pre-entry visit, were included in the study. Subjects were excluded if they had  
56  
57 experienced clinically significant illness in the 2 weeks before enrolment, had a history of  
58  
59  
60

1  
2  
3 clinically significant comorbidity, were taking any prescribed medication in the 2 weeks  
4 before first administration of lesogaberan, were taking over-the-counter medication in  
5 the week before first administration of lesogaberan (with the exception of paracetamol or  
6 nasal spray), or had a previously noted LES pressure of < 5 mmHg. Smoking or other  
7 nicotine use was not permitted during each visit or in the preceding 24 hours.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 This study was performed in accordance with the ethical principles of the Declaration of  
18 Helsinki, and the International Conference on Harmonisation Guidelines for Good Clinical  
19 Practice, and was approved by the Institutional Review Board of the study centre. All  
20 participants provided written informed consent before any study-related activities or  
21 procedures.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 **Study design and study drugs**

33 This was a single-blind, placebo-controlled, randomized, single-centre, phase 1 crossover  
34 study. Subjects fasted overnight before each study visit; food after 22:00 h and fluid after  
35 24:00 h on the preceding evening were not permitted.  
36  
37  
38  
39  
40  
41  
42

43 Following initial screening to assess eligibility and a run-in period of up to 14 days, each  
44 subject received a single low dose of lesogaberan (0.4 mg/kg oral solution) followed by a  
45 safety evaluation, which included a follow-up visit 48 hours after administration of the drug.  
46  
47  
48  
49  
50 If no clinically significant adverse events occurred, the subject was randomized, after a  
51 washout period of at least 5 days, to a single-blind, three-period, crossover phase in which  
52 each subject received single doses of lesogaberan (0.8 mg/kg oral solution), baclofen (40 mg  
53 capsule) and placebo, each separated by a washout period of at least 7 days. Esophageal  
54 manometric and pH-metric data were collected in the 4 hours following the dose and subjects  
55  
56  
57  
58  
59  
60



1  
2  
3 received a standardized meal (minced beef, potatoes, butter, banana and a soft drink; 2929 kJ  
4  
5 [30% fat]) 45 minutes after drug or placebo administration, to be consumed within  
6  
7  
8 15 minutes (Figure 1).  
9

### 10 11 12 **Assignment and blinding**

13  
14 A dosing regimen allocation list was generated by AstraZeneca R&D Mölndal using a  
15  
16 validated computer program. Dosing sequences according to a Latin square design balanced  
17  
18 for carry-over effects were randomized to subject numbers (assigned sequentially as eligible  
19  
20 subjects entered the study). The randomization was performed within blocks of consecutive  
21  
22 subject numbers. Dose allocation was blinded for the subjects and for personnel evaluating  
23  
24 the manometric/pH recordings but it remained open to other study personnel. Blinding was  
25  
26 maintained using the double-dummy principle. To standardize the intake of fluids, all doses  
27  
28 were diluted with sodium chloride solution 8 mg/mL to a volume of 50 mL.  
29  
30  
31  
32  
33  
34  
35

### 36 **Pharmacodynamic assessments**

37  
38 Manometric recordings from the pharynx, esophagus, LES and stomach were obtained using  
39  
40 a perfused 10-channel silicone rubber assembly (Dentsleeve Pty Ltd, Adelaide, Australia). A  
41  
42 sleeve with one side-hole for pharyngeal recordings and side-holes at 3 cm intervals for  
43  
44 recordings in the proximal, middle and distal esophagus was used. A perfused sleeve with  
45  
46 one side-hole on its proximal border and one intragastric side-hole (2 cm distal to the sleeve)  
47  
48 was used to record LES pressure. Pressures were recorded with external pressure transducers  
49  
50 (Baxter, Uden, the Netherlands). The assembly was perfused with degassed water at a rate of  
51  
52 0.3 mL/min (esophagus) and 0.6 mL/min (sleeve) using low compliance hydraulic flow  
53  
54 restrictors (DentSleeve International Ltd, Mississauga, Ontario, Canada) and a portable water  
55  
56 pump. The catheter was positioned with the proximal border of the sleeve 1 cm above the  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

LES. Esophageal pH was measured using a glass electrode with built-in reference (model LOT 440, Ingold A.G., Urdorf, Switzerland), positioned 5 cm above the proximal margin of the LES. The manometric and pH data signals were sampled at a frequency of 16 Hz.

Subjects were in a sitting position during the manometric/pH recording.

The following variables were assessed for lesogaberan, baclofen and placebo based on manometric and pH tracings recorded from dosing to the end of the 3-hour postprandial period (excluding parts of the tracing recorded during consumption of the standardized meal).

- Number of TLESRs (defined according to previously described criteria<sup>24</sup>).
- Number of acid reflux episodes (defined as a period of more than 4 seconds during which intra-esophageal pH fell below 4 or fell by at least 1 unit if the pH was already below 4).
- Number of TLESRs temporally related to acid reflux episodes (defined as a TLESR during which there was a drop in esophageal pH).
- LES pressure (recorded every 15 minutes and expressed as the mean difference between the end-expiration LES pressure and the end-expiration intragastric pressure over 1 minute). Mean LES pressure during the 3-hour postprandial period was calculated from measurements taken from 15 minutes after the end of the meal and then every 15 minutes until 3 hours after the meal.
- Number of swallows (defined as a fast increase in pressure in the pharyngeal channel, clearly distinguishable from baseline activity).

### Safety and tolerability assessments

Each subject underwent a physical examination in the 14 day period before the first study visit, including pulse and blood pressure measurements, together with full screening of

1  
2  
3 laboratory values and electrocardiogram (ECG) recording. These tests were repeated on the  
4 final follow-up visit 2–5 days after administration of the last drug/placebo. During each study  
5 visit, subjects were continuously monitored for safety for the first 4 hours after dose  
6 administration using a two-lead ECG system equipped with an alarm function. Pulse, and  
7 systolic and diastolic blood pressure were measured at all visits. Data on adverse events were  
8 collected from administration of first study drug until the final follow-up visit 2–5 days after  
9 administration of the last drug/placebo.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 **Pharmacokinetic assessments**

23  
24 Multiple blood samples (4 mL) were collected during the study visits during which  
25 lesogaberan and baclofen were administered for determination of area under the plasma  
26 concentration versus time curve ( $AUC_t$ ), maximum plasma concentration ( $C_{max}$ ) and time to  
27 reach maximum plasma concentration ( $t_{max}$ ) for lesogaberan and baclofen. Plasma  
28 concentrations of lesogaberan and baclofen were determined by liquid chromatography and  
29 mass spectrometry. The limits of quantification of lesogaberan and baclofen in plasma were  
30 0.030  $\mu\text{mol/L}$  and 0.020  $\mu\text{mol/L}$ , respectively. For each subject, one plasma sample taken  
31 during placebo dosing was analysed to confirm that these subjects had not been given  
32 lesogaberan or baclofen.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Statistical analysis**

49  
50 All subjects who received at least one dose of lesogaberan, baclofen or placebo were included  
51 in the safety analysis. The analysis of pharmacodynamic effects included all subjects who  
52 completed the study.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The analysis of  $AUC_t$ ,  $C_{max}$ , number of TLESRs, number of acid reflux episodes and number  
4 of swallows was based on an analysis of variance (ANOVA) model, with dosing regimen,  
5 period and sequence as fixed effects and subject as a random effect. The difference in LES  
6 pressure was analysed using a paired *t*-test of the logarithm of the mean postprandial  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The point estimate and the limits of the confidence interval (CI) for the log transformed variables were transformed using the antilogarithm to give estimates of the ratio of geometric means and corresponding CIs.

The  $AUC_t$ ,  $C_{max}$ , number of TLESRs and LES pressure were log-transformed in the analysis. CIs for the true mean were calculated in the logarithmic scale based on the mean square error obtained in the ANOVA. The limits were transformed back to the original scale to give a CI for the geometric mean for each dosing regimen or the ratio of geometric means between dosing regimens. Untransformed pharmacodynamic and pharmacokinetic variables, except  $t_{max}$ , were analysed in terms of arithmetic means and 95% CIs. Each CI was based on Student's *t*-distribution. The median, minimum, and maximum values are given for  $t_{max}$ .

No formal calculation of sample size was performed. However, based on general considerations, a sample size of 20 evaluable subjects was expected to be large enough to evaluate reductions in the number of TLESRs.

## RESULTS

### Participant flow and follow-up

The first subject enrolled in the study in September 2003 and the last subject completed the study in February 2004. In total, 27 healthy men were enrolled in the study. Two of these

1  
2  
3 subjects no longer met the inclusion criteria at the first visit and one withdrew consent,  
4  
5 leaving 24 eligible subjects who received the low dose of lesogaberan (0.4 mg/kg). These  
6  
7 24 subjects were all subsequently randomized to receive lesogaberan 0.8 mg/kg, baclofen 40  
8  
9 mg or placebo. After randomization, one subject withdrew consent and two were  
10  
11 discontinued because of low LES pressure. Twenty-one subjects therefore completed the  
12  
13 study. All 24 randomized subjects received lesogaberan 0.4 mg/kg and were included in the  
14  
15 pharmacokinetic and safety analyses. The 21 randomized subjects who completed the study  
16  
17 were included in the pharmacodynamic analyses.  
18  
19  
20  
21  
22  
23  
24

### 25 **Subject demographics and clinical characteristics at baseline**

26  
27 All subjects were male and Caucasian. The mean age was 27 years (range: 18–50 years) and  
28  
29 the mean body mass index was 23.7 kg/m<sup>2</sup> (range: 19.4–28.1 kg/m<sup>2</sup>). At the time of  
30  
31 enrolment, all subjects had normal blood pressure, pulse and ECG recordings, and all were  
32  
33 found to be healthy on physical examination.  
34  
35  
36  
37  
38

### 39 **Analysis**

#### 40 *Pharmacodynamic results*

41  
42 Figure 2 shows the number of TLESRs in individual subjects during the 3 hours following  
43  
44 the standardized meal, which was ingested between 45 and 60 minutes after dosing.  
45  
46

47  
48 Compared with placebo, lesogaberan 0.8 mg/kg significantly reduced the geometric mean  
49  
50 number of TLESRs by 36% (geometric mean ratio [GMR]: 0.64; 95% CI: 0.51–0.82;  
51

52  
53 Table 1). Baclofen 40 mg, used as a positive control, significantly reduced the number of  
54  
55 TLESRs by 47% compared with placebo (GMR: 0.53; 95% CI: 0.41–0.67; Table 1). The  
56

57  
58 relative effects of both lesogaberan and baclofen compared with placebo were greatest during  
59  
60 the first postprandial hour (Figure 3).

**Table 1.** Pharmacodynamic effects of lesogaberan 0.8 mg/kg and baclofen 40 mg compared with placebo during the 3 hours after the meal, which was completed 1 hour after dose administration (n = 21).

	Placebo	Lesogaberan 0.8 mg/kg	Baclofen 40 mg
Geometric mean number of TLESRs	13.0	8.3	6.8
Geometric mean LES pressure (mmHg)	7.2	10.0	10.4
Mean number of acid reflux episodes	3.6	2.0	1.4
Mean number of swallows	66.3	69.5	55.9

LES, lower esophageal sphincter; TLESR, transient lower esophageal sphincter relaxation.

The mean LES pressure after dosing with lesogaberan 0.8 mg/kg or placebo is shown in Figure 4. Over the 3 hours after the meal, the geometric mean LES pressure was significantly increased by 39% with lesogaberan 0.8 mg/kg compared with placebo (Table 1; GMR: 1.39; 95% CI: 1.18–1.64).

Lesogaberan 0.8 mg/kg significantly reduced the number of acid reflux episodes compared with placebo during the 3 hours after the meal, with an arithmetic mean reduction of 1.6 acid reflux episodes (95% CI: 0.34–2.9). The number of acid reflux episodes in individual subjects is presented in Figure 5 and mean values are given in Table 1. The reduction in acid reflux episodes was apparent by the first hour after the meal and was sustained until the end of the pharmacodynamic assessment period (Figure 6). Baclofen also reduced the number of acid reflux episodes compared with placebo, by a mean of 2.2 episodes (95% CI: 0.94–3.5).

1  
2  
3  
4  
5  
6 The proportion of TLESRs temporally related to an acid reflux episode during the 3 hours  
7  
8 after the meal were 18.9%, 18.7% and 23.9% with lesogaberan 0.8 mg/kg, baclofen 40 mg  
9  
10 and placebo, respectively. For all three dosing regimens, the majority of acid reflux episodes  
11  
12 were temporally related to a TLESR during the 3 hours after the meal (81.9% for lesogaberan  
13  
14 0.8 mg/kg, 91.4% for baclofen 40 mg and 82.6% for placebo).

15  
16  
17  
18  
19  
20 There were similar numbers of swallows with lesogaberan 0.8 mg/kg and placebo (mean  
21  
22 difference of 3.2 swallows; 95% CI: -5.5 to 11.8). Baclofen 40 mg reduced the number of  
23  
24 swallows by a mean of 10.4 compared with placebo (95% CI: -1.8 to -19.0). Mean values are  
25  
26 given in Table 1.  
27  
28  
29  
30  
31

### 32 ***Safety results***

33  
34 A single dose of lesogaberan (0.4 mg/kg or 0.8 mg/kg) had no clinically significant effects on  
35  
36 vital signs, ECG or laboratory values. Adverse events reported during the study are presented  
37  
38 in Table 2. No serious adverse events were reported and no participants discontinued the  
39  
40 study because of adverse events.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Number of subjects reporting adverse events during active dosing (safety population).

	Lesogaberan 0.4 mg/kg (single dose) (n = 24)	Lesogaberan 0.8 mg/kg (single dose) (n = 21)	Baclofen 40 mg (single dose) (n = 22)	Placebo (n = 22)
Any adverse event	6	10	16	10
Serious adverse event	0	0	0	0
Discontinuation due to adverse event	0	0	0	0
<i>Most frequently reported adverse events (reported by <math>\geq 2</math> subjects)</i>				
Nervous system disorders	5	7	14	6
Paraesthesia	4	4	3	0
Headache	2	0	6	2
Somnolence	0	3	4	2
Dizziness	0	0	5	2
Burning sensation	0	1	1	0
Investigations	3	0	0	0
Urine output increased	2	0	0	0
Gastrointestinal disorders	0	2	2	3



	Lesogaberan 0.4 mg/kg (single dose) (n = 24)	Lesogaberan 0.8 mg/kg (single dose) (n = 21)	Baclofen 40 mg (single dose) (n = 22)	Placebo (n = 22)
Abdominal distension	0	0	0	2
Abdominal pain	0	2	0	0
Abdominal pain, upper	0	1	0	1
General disorders	0	1	2	2
Feeling hot	0	0	1	2
Fatigue	0	1	1	0

Overall, 22/24 subjects reported an adverse event; 16/22 with baclofen, 10/21 with lesogaberan 0.8 mg/kg and 10/22 with placebo. Of these adverse events, 15 for baclofen and 8 each for lesogaberan and placebo were considered to be attributable to the study drug. Similar numbers of nervous system adverse events were reported after a single dose of lesogaberan 0.8 mg/kg (7/21) and placebo (6/22), but almost twice as many were reported after a single dose of baclofen 40 mg (14/22).

The most commonly reported adverse event during active dosing with lesogaberan 0.8 mg/kg was transient paraesthesia (reported by 4/21 subjects), which was mild or moderate in intensity. The onset of paraesthesia occurred 1–63 minutes after administration of lesogaberan 0.8 mg/kg and the symptoms quickly resolved, within 3–60 minutes. Three

1  
2  
3 subjects reported paraesthesia with baclofen 40 mg, occurring 13–165 minutes after dose  
4  
5 administration, and symptoms resolved within 10–125 minutes.  
6  
7  
8  
9

### 10 *Pharmacokinetic results*

11  
12 Lesogaberan 0.8 mg/kg was rapidly absorbed with a median  $t_{\max}$  of 1.0 hour; geometric mean  
13  
14 values for  $C_{\max}$  and  $AUC_t$  were 1.60  $\mu\text{mol/L}$  and 6.47  $\mu\text{mol}\cdot\text{h/L}$ , respectively. Baclofen was  
15  
16 also rapidly absorbed with a median  $t_{\max}$  of 1.5 hours; geometric mean values for  $C_{\max}$  and  
17  
18  $AUC_t$  were 2.29  $\mu\text{mol/L}$  and 9.61  $\mu\text{mol}\cdot\text{h/L}$ , respectively. Figure 7 shows the mean plasma  
19  
20 concentrations of lesogaberan and baclofen in the 12 hours after dosing.  
21  
22  
23  
24  
25  
26

## 27 **DISCUSSION**

28  
29 This randomized, single-blind, placebo-controlled, crossover study is the first to show that  
30  
31 the novel GABA<sub>B</sub>-receptor agonist lesogaberan reduces the number of TLESRs in the  
32  
33 postprandial period in humans. These findings show that a single dose of lesogaberan is able  
34  
35 to modulate the most important underlying mechanism of reflux in humans, as well as in  
36  
37 animals.  
38  
39  
40  
41  
42

43 TLESR is the predominant mechanism underlying reflux in GERD,<sup>13,14</sup> and use of  
44  
45 pharmacological agents to reduce the number of TLESRs has been shown also to reduce the  
46  
47 occurrence of reflux episodes in healthy subjects and patients with GERD.<sup>25,26</sup> In dogs,  
48  
49 lesogaberan has been shown to inhibit TLESRs in a dose-dependent manner.<sup>21</sup> In the current  
50  
51 study in healthy **male** subjects, a single oral dose of lesogaberan 0.8 mg/kg reduced the  
52  
53 number of TLESRs by approximately 36% compared with placebo. As expected, lesogaberan  
54  
55 had the greatest effect on TLESRs relative to placebo in the first postprandial hour, but the  
56  
57 effect was demonstrated throughout the 4 hours after dosing. The effect of lesogaberan on the  
58  
59  
60

1  
2  
3 number of TLESRs was similar to that of baclofen (reduction of 47%). This is comparable to  
4  
5 findings from previous studies with baclofen in healthy subjects and patients with GERD.<sup>17,18</sup>  
6  
7  
8

9  
10 As expected in healthy subjects, the number of reflux episodes with all dosing regimens was  
11  
12 low. Lesogaberan significantly reduced the number of acid reflux episodes to a similar extent  
13  
14 to baclofen. Given that the majority of acid reflux episodes were temporally related to a  
15  
16 TLESR, the reduction in the number of acid reflux episodes was probably largely due to the  
17  
18 reduction in the number of TLESRs. Lesogaberan also increased LES pressure by  
19  
20 approximately 39%, which may have contributed to the reduction in reflux episodes, but the  
21  
22 exact importance of increased LES pressure remains unknown. The timing and magnitude of  
23  
24 LES pressure increase is comparable to that of baclofen, with a maximal increase in the  
25  
26 second and third postprandial hours. The increase in LES pressure observed with lesogaberan  
27  
28 is likely to be provoked at a peripheral level,<sup>23</sup> although very little is known about the  
29  
30 mechanisms that govern LES pressure.<sup>27</sup> Together, these data in healthy men support the  
31  
32 future assessment of lesogaberan as a potential treatment for patients with GERD with  
33  
34 persistent symptoms despite daily PPI therapy.  
35  
36  
37  
38  
39  
40  
41  
42

43 The clinical usefulness of the GABA<sub>B</sub>-receptor agonist baclofen in the treatment of GERD is  
44  
45 limited because of the common occurrence of adverse CNS effects.<sup>26</sup> Similarly, although a  
46  
47 phase 1 study has demonstrated that the GABA<sub>B</sub>-receptor agonist AZD9343 reduces the  
48  
49 number of TLESRs, this compound was found to be associated with adverse events such as  
50  
51 somnolence.<sup>28</sup> In contrast to baclofen, lesogaberan has a lower propensity to cause adverse  
52  
53 CNS events because of its higher affinity for the GABA carrier.<sup>23</sup> This stronger binding to the  
54  
55 GABA carrier results in low extracellular lesogaberan levels in the CNS and therefore a low  
56  
57 potential for interaction with central GABA<sub>B</sub> receptors.<sup>23</sup> In the current study, nervous system  
58  
59  
60

1  
2  
3 adverse events were reported by a similar number of subjects taking lesogaberan (7/21) to  
4 those taking placebo (6/22), but by approximately twice as many subjects (14/22) during  
5 **dosing** with baclofen. As expected, dizziness was one of the most commonly reported  
6  
7  
8  
9  
10 adverse events with baclofen; dizziness was not reported by any subjects during **dosing** with  
11  
12 lesogaberan, but was reported by two subjects while on placebo. There was no clear  
13  
14  
15 difference between any of the **dosing regimens** in terms of the occurrence of somnolence  
16  
17  
18 (2/22 for placebo, 3/21 for lesogaberan and 4/22 with baclofen).

19  
20  
21  
22 A decrease in the frequency of spontaneous swallowing may be a central effect,<sup>29</sup> and this  
23  
24 was observed with baclofen but not lesogaberan, further suggesting a peripheral rather than a  
25  
26 central action for lesogaberan. In line with this, transient paraesthesia was reported by four  
27  
28 subjects taking lesogaberan. Paraesthesia was consistently mild to moderate and short in  
29  
30 duration, as has been reported in other studies of lesogaberan.<sup>30,31</sup> The underlying cause  
31  
32 of paraesthesia associated with the intake of lesogaberan is not known, but it may be  
33  
34 speculated that the observed rapid onset of paraesthesia is a result of lesogaberan stimulating  
35  
36 GABA<sub>B</sub> receptors located in peripheral cutaneous afferents, causing changes in membrane  
37  
38 potential and an imbalance in the sensory input.<sup>32,33</sup> Interestingly, paraesthesia was also  
39  
40 reported by three subjects taking baclofen in this study. According to other studies,  
41  
42 occurrence of paraesthesia after baclofen administration is rare, possibly because baclofen  
43  
44 has a lower selectivity and potency for GABA<sub>B</sub> receptors than lesogaberan, which results in a  
45  
46 slower rate of binding to the receptors.<sup>34</sup> It is possible that the reports of paraesthesia in the  
47  
48 subjects taking baclofen were a consequence of paraesthesia being described in the patient  
49  
50 information leaflet for the study, although paraesthesia was not reported by any subject while  
51  
52 on placebo. Transient paraesthesia is considered to be an uncomfortable rather than painful  
53  
54 sensation, and did not cause any patients to withdraw from the current study. Moreover,  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

lesogaberan had no clinically significant effects on vital signs, ECG or laboratory values at any dose and no serious adverse events were reported during the study. Indeed, the total number of subjects experiencing an adverse event was very similar in the lesogaberan and placebo groups (10/21 and 10/22, respectively). Although the incidence of paraesthesia warrants further investigation, the collective data suggest a potential clinical advantage of lesogaberan over baclofen.

Acid suppression is an effective way to reduce the acidity of refluxate, and the clinical efficacy of PPIs is well established. The most promising treatment approach for the 20–30% of patients who experience persistent GERD symptoms despite PPI therapy appears to be an add-on therapy with a novel mode of action that could complement acid suppression. Reflux inhibition is attractive because it has the potential to prevent all types of reflux events, including weakly acidic and weakly alkaline reflux, which are known to generate symptoms in patients taking PPIs.<sup>11,12</sup>

In conclusion, the decreases in the number of TLESRs and reflux episodes in healthy men receiving lesogaberan, along with the increase in LES pressure, support further assessment of this novel GABA<sub>B</sub>-receptor agonist as a potential add-on therapy in patients with GERD with persistent symptoms despite daily PPI therapy. Accordingly, several phase II clinical trials assessing lesogaberan in this patient group are currently at the recruitment or analysis stage (ClinicalTrials.gov Identifiers: NCT00743444, NCT01043185, NCT01005251 and NCT00394472).

## FIGURE LEGENDS

**Figure 1.** Schedule of dosing, standardized meal and pharmacological assessments during each treatment period.

**Figure 2.** Number of TLESRs in individual subjects taking placebo, lesogaberan 0.8 mg/kg and baclofen 40 mg, during the 3 hours after a standardized meal, which was completed 1 hour after drug administration (n = 21).

TLESR, transient lower esophageal sphincter relaxation.

**Figure 3.** Mean number of TLESRs in subjects taking placebo, lesogaberan 0.8 mg/kg or baclofen 40 mg, during the pre-meal period (0–45 minutes after dose intake), and during the first, second and third hours after a standardized meal, which was completed 1 hour after dose intake (n = 21).

Bars indicate 95% confidence intervals.

TLESR, transient lower esophageal sphincter relaxation.

**Figure 4.** Mean LES pressure during the 4 hours following administration of placebo compared with (a) lesogaberan 0.8 mg/kg (n = 21) and (b) baclofen 40 mg (n = 21).

Bars show 95% confidence intervals.

LES, lower esophageal sphincter.

**Figure 5.** Number of acid reflux episodes in individual subjects taking placebo, lesogaberan 0.8 mg/kg and baclofen 40 mg, in the 3 hours after the standardized meal, which was completed 1 hour after dose administration (n = 21).

1  
2  
3 **Figure 6.** Mean number of acid reflux episodes in subjects taking placebo, lesogaberan 0.8  
4 mg/kg and baclofen 40 mg, during the pre-meal period (0–45 minutes after dose intake) and  
5 the first, second and third hours after the standardized meal, which was completed 1 hour  
6 after dose intake (n = 21).  
7  
8  
9

10  
11  
12 Bars show 95% confidence intervals.  
13  
14

15  
16  
17 **Figure 7.** Mean plasma concentration of lesogaberan and baclofen during the 12 hours after  
18 dosing with lesogaberan 0.8 mg/kg or baclofen 40 mg (n = 21).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**1. Authors' declaration of personal interests:**

- (i) GEB has served as a speaker, a consultant or an advisory board member for AstraZeneca, GSK, Movetis, Norgine and Johnson & Johnson, and has received research funding from AstraZeneca.
- (ii) HR, JA and MR are employees of AstraZeneca.
- (iii) AL has no competing interests to disclose.

**2. Declaration of funding interests:**

- (i) This study was supported by AstraZeneca R&D Mölndal, Sweden.
- (ii) The writing of this paper was funded by AstraZeneca R&D Mölndal, Sweden.
- (iii) Writing support was provided by Dr Catherine Henderson of Oxford PharmaGenesis Ltd, Oxford, UK and funded by AstraZeneca R&D Mölndal, Sweden (study code D9120C00001).



**REFERENCES**

- 1 Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. *Aliment Pharmacol Ther* 2008; 28: 841–53.
- 2 Wiklund I, Talley NJ. Update on health-related quality of life in patients with gastroesophageal reflux disease. *Expert Rev Pharmacoeconomics Outcomes Res* 2003; 3: 341–50.
- 3 Vakil N, Veldhuyzen van Zanten S, Kahrilas P, *et al.* The Montreal definition and classification of gastro-esophageal reflux disease (GERD) – a global evidence-based consensus. *Am J Gastroenterol* 2006; 101: 1900–20.
- 4 Bredenoord AJ, Weusten BL, Curvers WL, *et al.* Determinants of perception of heartburn and regurgitation. *Gut* 2006; 55: 313–18.
- 5 van Pinxteren B, Numans ME, Bonis PA, *et al.* Short-term treatment with proton pump inhibitors, H<sub>2</sub>-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev* 2004: CD002095.
- 6 Donnellan C, Sharma N, Preston C, *et al.* Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. *Cochrane Database Syst Rev* 2005; 4: CD003245.
- 7 Armstrong D, Pare P, Pericak D, *et al.* Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. *Am J Gastroenterol* 2001; 96: 2849–57.
- 8 Hatlebakk JG, Hyggen A, Madsen PH, *et al.* Heartburn treatment in primary care: randomised, double blind study for 8 weeks. *BMJ* 1999; 319: 550–3.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 9 Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, *et al.* Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. *Aliment Pharmacol Ther* 2004; 19: 907–15.
- 10 Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. *Drugs* 2007; 67: 1521–30.
- 11 Mainie I, Tutuian R, Shay S, *et al.* Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006; 55: 1398–402.
- 12 Vela MF, Camacho-Lobato L, Srinivasan R, *et al.* Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. *Gastroenterology* 2001; 120: 1599–606.
- 13 Dent J, Dodds WJ, Friedman RH, *et al.* Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980; 65: 256–67.
- 14 Dodds WJ, Dent J, Hogan WJ, *et al.* Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. *N Engl J Med* 1982; 307: 1547–52.
- 15 Smid SD, Young RL, Cooper NJ, *et al.* GABA(B)R expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. *Am J Physiol Gastrointest Liver Physiol* 2001; 281: G1494–501.
- 16 McDermott CM, Abrahams TP, Partosoedarso E, *et al.* Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. *Gastroenterology* 2001; 120: 1749–62.
- 17 Lidums I, Lehmann A, Checklin H, *et al.* Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. *Gastroenterology* 2000; 118: 7–13.

- 1  
2  
3 18 Zhang Q, Lehmann A, Rigda R, *et al.* Control of transient lower oesophageal  
4 sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-  
5 oesophageal reflux disease. *Gut* 2002; 50: 19–24.  
6  
7  
8  
9  
10 19 Vela MF, Tutuian R, Katz PO, *et al.* Baclofen decreases acid and non-acid post-  
11 prandial gastro-oesophageal reflux measured by combined multichannel intraluminal  
12 impedance and pH. *Aliment Pharmacol Ther* 2003; 17: 243–51.  
13  
14  
15  
16  
17 20 Koek GH, Sifrim D, Lerut T, *et al.* Effect of the GABA(B) agonist baclofen in  
18 patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump  
19 inhibitors. *Gut* 2003; 52: 1397–402.  
20  
21  
22  
23  
24 21 Lehmann A, Brändén L, Carlsson A, *et al.* AZD3355, a novel GABA(B) receptor  
25 agonist, inhibits transient lower esophageal sphincter relaxations in the dog [abstract].  
26  
27  
28  
29  
30  
31  
32 22 Brändén L, Carlsson A, Jensen J, *et al.* The novel GABA(B) receptor agonist  
33 AZD3355 inhibits acid reflux and reduces esophageal acid exposure as measured by 24h  
34 pHmetry in dogs [abstract]. *Gastroenterology* 2008; 134(4 Suppl 1): A715.  
35  
36  
37  
38  
39 23 Lehmann A, Blackshaw LA, Elebring T, *et al.* The new reflux inhibitor AZD3355 has  
40 a low propensity for inducing central side effects due to its affinity for the GABA carrier  
41 [abstract]. *Gastroenterology* 2008; 134(4 Suppl 1): A715.  
42  
43  
44  
45  
46 24 Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient  
47 lower esophageal sphincter relaxation. *Am J Physiol* 1995; 268: G128–33.  
48  
49  
50  
51 25 Hirsch DP, Tytgat GN, Boeckxstaens GE. Transient lower oesophageal sphincter  
52 relaxations – a pharmacological target for gastro-oesophageal reflux disease? *Aliment*  
53  
54  
55  
56  
57  
58 26 Lehmann A. Novel treatments of GERD: focus on the lower esophageal sphincter.  
59  
60  
*Eur Rev Med Pharmacol Sci* 2008; 12: 103–10.

- 1  
2  
3 27 Dent J. Pathogenesis of gastro-oesophageal reflux disease and novel options for its  
4 therapy. *Neurogastroenterol Motil* 2008; 20 Suppl 1: 91–102.  
5  
6  
7  
8 28 Beaumont H, Smout A, Aanen M *et al.* The GABA<sub>B</sub> receptor agonist AZD9343  
9 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy  
10 volunteers: a phase I study. *Aliment Pharmacol Ther* 2009; 30: 937–46.  
11  
12  
13  
14  
15 29 Lehmann A, Bremner-Danielsen M, Brändén L, *et al.* Inhibitory effects of GABA(B)  
16 receptor agonists on swallowing in the dog. *Eur J Pharmacol* 2002; 448: 67–70.  
17  
18  
19  
20 30 Boeckxstaens GE, Denison H, Ruth M, *et al.* Effect of AZD3355, a novel GABA(B)  
21 agonist, on reflux and lower esophageal sphincter function in patients with GERD with  
22 symptoms despite proton pump inhibitor treatment [abstract]. *Gastroenterol* 2009; 136(Suppl  
23 1): M1861.  
24  
25  
26  
27  
28  
29 31 Boeckxstaens GE, Beaumont H, Hatlebakk JG, *et al.* Efficacy and tolerability of the  
30 novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms  
31 despite proton pump inhibitor therapy [abstract]. *Gastroenterol* 2009; 136(Suppl 1): M1875.  
32  
33  
34  
35  
36 32 Mogyoros I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy  
37 axons. *Muscle Nerve* 2000; 23: 310–20.  
38  
39  
40  
41 33 Brown DA, Adams PR, Higgins AJ, *et al.* Distribution of GABA-receptors and  
42 GABA-carriers in the mammalian nervous system. *J Physiol (Paris)* 1979; 75: 667–71.  
43  
44  
45  
46 34 Alstermark C, Amin K, Dinn SR, *et al.* Synthesis and pharmacological evaluation of  
47 novel gamma-aminobutyric acid type B (GABA<sub>B</sub>) receptor agonists as gastroesophageal  
48 reflux inhibitors. *J Med Chem* 2008; 51: 4315–20.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Schedule of dosing, standardized meal and pharmacological assessments during each treatment period.  
98x38mm (600 x 600 DPI)

Peer Review




Figure 2. Number of TLESRs in individual subjects taking placebo, lesogaberan 0.8 mg/kg and baclofen 40 mg, during the 3 hours after a standardized meal, which was completed 1 hour after drug administration (n = 21). TLESR, transient lower esophageal sphincter relaxation.  
78x52mm (600 x 600 DPI)




Figure 3. Mean number of TLESRs in subjects taking placebo, lesogaberan 0.8 mg/kg or baclofen 40 mg, during the pre-meal period (0-45 minutes after dose intake), and during the first, second and third hours after a standardized meal, which was completed 1 hour after dose intake (n = 21).

Bars indicate 95% confidence intervals.

TLESR, transient lower esophageal sphincter relaxation.

81x60mm (600 x 600 DPI)




Figure 4. Mean LES pressure during the 4 hours following administration of placebo compared with (a) lesogaberan 0.8 mg/kg (n = 21) and (b) baclofen 40 mg (n = 21).

Bars show 95% confidence intervals.

LES, lower esophageal sphincter.

78x119mm (600 x 600 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 5. Number of acid reflux episodes in individual subjects taking placebo, lesogaberan 0.8 mg/kg and baclofen 40 mg, in the 3 hours after the standardized meal, which was completed 1 hour after dose administration (n = 21).  
77x53mm (600 x 600 DPI)

Review




Figure 6. Mean number of acid reflux episodes in subjects taking placebo, lesogaberan 0.8 mg/kg and baclofen 40 mg, during the pre-meal period (0-45 minutes after dose intake) and the first, second and third hours after the standardized meal, which was completed 1 hour after dose intake (n = 21).

Bars show 95% confidence intervals.  
83x62mm (600 x 600 DPI)




Figure 7. Mean plasma concentration of lesogaberan and baclofen during the 12 hours after dosing with lesogaberan 0.8 mg/kg or baclofen 40 mg (n = 21).  
84x55mm (600 x 600 DPI)

Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Alimentary Pharmacology & Therapeutic**  
**CONSORT Statement 2001 Checklist**  
**Items to include when reporting a randomized trial**

<i>PAPER SECTION And topic</i>	<b>Item</b>	<b>Descriptor</b>	<b>Reported on Page #</b>
<i>TITLE &amp; ABSTRACT</i>	1	<u>How participants were allocated to interventions</u> (e.g., "random allocation", "randomized", or "randomly assigned").	1 and 3
<i>INTRODUCTION</i> Background	2	<u>Scientific background and explanation of rationale.</u>	4 and 5
<i>METHODS</i> Participants	3	<u>Eligibility criteria for participants</u> and the <u>settings and locations where the data were collected.</u>	5 and 6
Interventions	4	<u>Precise details of the interventions intended for each group and how and when they were actually administered.</u>	6 and 7
Objectives	5	<u>Specific objectives and hypotheses.</u>	
Outcomes	6	<u>Clearly defined primary and secondary outcome measures</u> and, when applicable, any <u>methods used to enhance the quality of measurements</u> (e.g., multiple observations, training of assessors).	5, 8 and 9
Sample size	7	<u>How sample size was determined</u> and, when applicable, <u>explanation of any interim analyses and stopping rules.</u>	10
Randomization -- Sequence generation	8	<u>Method used to generate the random allocation sequence, including details of any restrictions</u> (e.g., blocking, stratification)	7
Randomization -- Allocation concealment	9	<u>Method used to implement the random allocation sequence</u> (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	7
Randomization -- Implementation	10	<u>Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.</u>	7
Blinding (masking)	11	<u>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.</u> If done, <u>how the success of blinding was evaluated.</u>	7
Statistical methods	12	<u>Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses</u> , such as subgroup analyses and adjusted analyses.	9 and 10
<i>RESULTS</i> Participant flow	13	<u>Flow of participants through each stage</u> (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. <u>Describe protocol deviations from study as planned, together with reasons.</u>	10 and 11
Recruitment	14	<u>Dates defining the periods of recruitment and follow-up.</u>	10
Baseline data	15	<u>Baseline demographic and clinical characteristics of each group.</u>	11
Numbers analyzed	16	<u>Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat".</u> State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	11
Outcomes and estimation	17	<u>For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision</u> (e.g., 95% confidence interval).	11–16
Ancillary analyses	18	<u>Address multiplicity by reporting any other analyses performed</u> , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	10
Adverse events	19	<u>All important adverse events or side effects in each intervention group.</u>	13–15
<i>DISCUSSION</i> Interpretation	20	<u>Interpretation of the results</u> , taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	16–18
Generalizability	21	<u>Generalizability (external validity) of the trial findings.</u>	16–18
Overall evidence	22	<u>General interpretation of the results in the context of current evidence.</u>	16–19

From Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001; 357(9263):1191-1194.

**The CONSORT Statement 2001 checklist is intended to be accompanied with the explanatory document that facilitates its use. For more information, visit [www.consort-statement.org](http://www.consort-statement.org).**